Literature DB >> 12164088

Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.

Min Seok Cho1, Kyun Sang Lee, Youn Kyoung Lee, Seong Kwon Ma, Jeong Hee Ko, Soo Wan Kim, Nam Ho Kim, Ki Chul Choi.   

Abstract

BACKGROUND: Patients on continuous ambulatory peritoneal dialysis (CAPD) have increased risk of low-turnover bone disease and relative hypoparathyroidism. Recently, it has been believed that magnesium plays an important role in regulating secretion of parathyroid hormone (PTH). The aim of this study was to evaluate the relationship between serum PTH and serum magnesium as a factor increasing the frequency of relative hypoparathyroidism.
METHODS: We analyzed the data of 56 patients who had been on CAPD for more than 6 months without any significant problems. No patient had been previously treated with vitamin D or aluminum hydroxide. The patients had used peritoneal dialysate with the magnesium concentration of 0.5 mEq/L. Biochemical parameters, such as BUN, creatinine, alkaline phosphatase bony isoenzyme, total protein, albumin, total calcium, ionized calcium and intact parathyroid hormone level were measured.
RESULTS: The mean serum magnesium level was 1.99 +/- 0.36 mEq/L. Among total 56 patients, 15 patients (26.8%) showed hypermagnesemia (serum magnesium > 2.2 mEq/L) and 5 patients (8.9%) showed hypomagnesemia (serum magnesium < 1.6 mEq/L). Among all 56 patients, serum iPTH (intact PTH) level was not correlated with serum magnesium level. However, it was inversely correlated with serum total calcium and ionized calcium levels, respectively (r = -0.365, p = 0.006; r = -0.515 p < 0.001). Among 49 patients whose serum iPTH level was less than 300 pg/mL, serum iPTH level was inversely correlated with serum magnesium level (r = -0.295, p = 0.039) and inversely correlated with serum total calcium and ionized calcium levels, respectively (r = -0.546, p < 0.001; r = -0.572 p < 0.001). Among 49 patients whose serum iPTH level was less than 300 pg/mL, lower iPTH group (serum iPTH < 120 pg/mL) showed higher serum magnesium level (p = 0.037), higher serum total calcium level (p < 0.001) and lower bone isoenzyme of alkaline phosphatase level (p < 0.001) than those of higher iPTH group (120 pg/mL < or = serum iPTH < 300 pg/mL).
CONCLUSION: Among the CAPD patients whose serum iPTH level was less than 300 pg/mL, there was a significant inverse correlation between serum iPTH level and serum magnesium level. This study indicates that not only serum calcium level but also serum magnesium level are important in the regulation of serum iPTH levels of CAPD patients who have been dialyzed by low-magnesium peritoneal dialysate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12164088      PMCID: PMC4531662          DOI: 10.3904/kjim.2002.17.2.114

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  27 in total

Review 1.  Calcium-sensing receptor and calcimimetic agents.

Authors:  J W Coburn; L Elangovan; W G Goodman; J M Frazaõ
Journal:  Kidney Int Suppl       Date:  1999-12       Impact factor: 10.545

Review 2.  Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate.

Authors:  J Silver; C Yalcindag; A Sela-Brown; R Kilav; T Naveh-Many
Journal:  Kidney Int Suppl       Date:  1999-12       Impact factor: 10.545

Review 3.  The role of calcium, phosphorus and vitamin D metabolism in the development of secondary hyperparathyroidism.

Authors:  E Slatopolsky
Journal:  Nephrol Dial Transplant       Date:  1998       Impact factor: 5.992

4.  Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients.

Authors:  J F Navarro; C Mora; A Jiménez; A Torres; M Macía; J García
Journal:  Am J Kidney Dis       Date:  1999-07       Impact factor: 8.860

5.  The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects.

Authors:  I N Cholst; S F Steinberg; P J Tropper; H E Fox; G V Segre; J P Bilezikian
Journal:  N Engl J Med       Date:  1984-05-10       Impact factor: 91.245

6.  Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium.

Authors:  P Nilsson; S G Johansson; B G Danielson
Journal:  Nephron       Date:  1984       Impact factor: 2.847

Review 7.  Magnesium in dialysis patients: serum levels and clinical implications.

Authors:  J F Navarro-González
Journal:  Clin Nephrol       Date:  1998-06       Impact factor: 0.975

8.  Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function.

Authors:  G Hercz; Y Pei; C Greenwood; A Manuel; C Saiphoo; W G Goodman; G V Segre; S Fenton; D J Sherrard
Journal:  Kidney Int       Date:  1993-10       Impact factor: 10.612

9.  Magnesium and parathyroid hormone changes to magnesium-free dialysate in continuous ambulatory peritoneal dialysis patients.

Authors:  S Takahashi; K Okada; M Yanai
Journal:  Perit Dial Int       Date:  1994       Impact factor: 1.756

10.  Hypomagnesemia in continuous ambulatory peritoneal dialysis patients dialyzed with a low-magnesium peritoneal dialysis solution.

Authors:  A A Ejaz; A P McShane; V C Gandhi; D J Leehey; T S Ing
Journal:  Perit Dial Int       Date:  1995       Impact factor: 1.756

View more
  9 in total

1.  Prevalence and factors associated with hypomagnesemia in Southern Chinese continuous ambulatory peritoneal dialysis patients.

Authors:  Hongjian Ye; Xiaodan Zhang; Qunying Guo; Naya Huang; Haiping Mao; Xueqing Yu; Xiao Yang
Journal:  Perit Dial Int       Date:  2013 Jul-Aug       Impact factor: 1.756

2.  Inverse correlation between serum magnesium and parathyroid hormone in peritoneal dialysis patients: a contributing factor to adynamic bone disease?

Authors:  Mingxin Wei; Khaled Esbaei; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

3.  Clinical Factors Associated with Serum Magnesium Concentration in Patients Undergoing Peritoneal Dialysis: A Single-Center Observational Study.

Authors:  Shohei Kaneko; Susumu Ookawara; Yoshiyuki Morishita
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-05-24

4.  Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients.

Authors:  John Cunningham; Mariano Rodríguez; Piergiorgio Messa
Journal:  Clin Kidney J       Date:  2012-02

5.  Lack of influence of serum magnesium levels on overall mortality and cardiovascular outcomes in patients with advanced chronic kidney disease.

Authors:  Olimpia Ortega; Isabel Rodriguez; Gabriela Cobo; Julie Hinostroza; Paloma Gallar; Carmen Mon; Milagros Ortiz; Juan Carlos Herrero; Cristina Di Gioia; Aniana Oliet; Ana Vigil
Journal:  ISRN Nephrol       Date:  2013-06-19

Review 6.  Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.

Authors:  Nigar Sekercioglu; Argie Angeliki Veroniki; Lehana Thabane; Jason W Busse; Noori Akhtar-Danesh; Alfonso Iorio; Luciane Cruz Lopes; Gordon H Guyatt
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

7.  Why are serum magnesium levels lower in Saudi dialysis patients?

Authors:  Ahmed H Mitwalli
Journal:  J Taibah Univ Med Sci       Date:  2016-10-15

8.  The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study.

Authors:  Paraish S Misra; Ahsan Alam; Mark L Lipman; Sharon J Nessim
Journal:  BMC Nephrol       Date:  2015-08-13       Impact factor: 2.388

9.  Hypomagnesemia Is Associated with Increased Mortality among Peritoneal Dialysis Patients.

Authors:  Kedan Cai; Qun Luo; Zhiwei Dai; Beixia Zhu; Jinping Fei; Congping Xue; Dan Wu
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.